Matt Miksic
Stock Analyst at Barclays
(4.07)
# 588
Out of 4,758 analysts
264
Total ratings
66.67%
Success rate
6.81%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $118 → $112 | $100.14 | +11.84% | 7 | Feb 10, 2025 | |
| SYK Stryker | Maintains: Overweight | $418 → $443 | $384.50 | +15.21% | 23 | Feb 10, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $111 → $118 | $105.99 | +11.33% | 16 | Feb 10, 2025 | |
| INMD InMode | Maintains: Overweight | $26 → $29 | $18.88 | +53.64% | 12 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $159 → $166 | $156.01 | +6.40% | 11 | Jan 28, 2025 | |
| ABT Abbott Laboratories | Maintains: Overweight | $149 → $158 | $131.47 | +20.18% | 28 | Jan 27, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $20 → $21 | $10.86 | +93.37% | 2 | Jan 22, 2025 | |
| AVR Anteris Technologies Global | Initiates: Overweight | $22 | $8.04 | +173.63% | 1 | Jan 7, 2025 | |
| OBIO Orchestra BioMed Holdings | Initiates: Overweight | $16 | $5.33 | +200.19% | 1 | Jan 2, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $85 → $88 | $75.41 | +16.70% | 27 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $109 | $91.23 | +19.47% | 21 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $234 | $281.18 | -16.78% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $60 | $32.84 | +82.73% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $93 | $83.89 | +10.86% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $113 | $84.08 | +34.40% | 5 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $490 → $510 | $589.21 | -13.44% | 6 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $13.11 | +22.04% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $61 | $47.83 | +27.54% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $18 | $16.68 | +7.95% | 4 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $52 → $54 | $30.41 | +77.57% | 19 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $96 | $89.80 | +6.90% | 9 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $77.69 | +28.72% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $205.69 | +103.22% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $13.43 | +108.57% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $18.49 | +262.36% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $12.20 | +3,834.43% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $24.18 | +259.80% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $3.61 | +592.52% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $8.37 | +7.53% | 1 | Dec 12, 2016 |
Zimmer Biomet Holdings
Feb 10, 2025
Maintains: Underweight
Price Target: $118 → $112
Current: $100.14
Upside: +11.84%
Stryker
Feb 10, 2025
Maintains: Overweight
Price Target: $418 → $443
Current: $384.50
Upside: +15.21%
Boston Scientific
Feb 10, 2025
Maintains: Overweight
Price Target: $111 → $118
Current: $105.99
Upside: +11.33%
InMode
Feb 5, 2025
Maintains: Overweight
Price Target: $26 → $29
Current: $18.88
Upside: +53.64%
Johnson & Johnson
Jan 28, 2025
Maintains: Equal-Weight
Price Target: $159 → $166
Current: $156.01
Upside: +6.40%
Abbott Laboratories
Jan 27, 2025
Maintains: Overweight
Price Target: $149 → $158
Current: $131.47
Upside: +20.18%
Alphatec Holdings
Jan 22, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.86
Upside: +93.37%
Anteris Technologies Global
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $8.04
Upside: +173.63%
Orchestra BioMed Holdings
Jan 2, 2025
Initiates: Overweight
Price Target: $16
Current: $5.33
Upside: +200.19%
Edwards Lifesciences
Dec 2, 2024
Maintains: Overweight
Price Target: $85 → $88
Current: $75.41
Upside: +16.70%
Nov 26, 2024
Maintains: Overweight
Price Target: $105 → $109
Current: $91.23
Upside: +19.47%
Nov 11, 2024
Maintains: Equal-Weight
Price Target: $220 → $234
Current: $281.18
Upside: -16.78%
Nov 8, 2024
Maintains: Overweight
Price Target: $58 → $60
Current: $32.84
Upside: +82.73%
Aug 8, 2024
Maintains: Overweight
Price Target: $85 → $93
Current: $83.89
Upside: +10.86%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $138 → $113
Current: $84.08
Upside: +34.40%
Jul 23, 2024
Maintains: Overweight
Price Target: $490 → $510
Current: $589.21
Upside: -13.44%
Mar 5, 2024
Maintains: Underweight
Price Target: $13 → $16
Current: $13.11
Upside: +22.04%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $57 → $61
Current: $47.83
Upside: +27.54%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $17 → $18
Current: $16.68
Upside: +7.95%
Feb 12, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $30.41
Upside: +77.57%
May 13, 2022
Assumes: Outperform
Price Target: $96
Current: $89.80
Upside: +6.90%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $77.69
Upside: +28.72%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $205.69
Upside: +103.22%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $13.43
Upside: +108.57%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $18.49
Upside: +262.36%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $12.20
Upside: +3,834.43%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $24.18
Upside: +259.80%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $3.61
Upside: +592.52%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $8.37
Upside: +7.53%